Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
AXDX.US
id: 936

Accelerate (AXDX) Product Discontinuation Case

  • In Oct. 2022, Accelerate disclosed the FDA-requested discontinuation of 2 products.
  • On it, $AXDX fell 39%, losing $9M+ shareholder value.
  • Now, investors may suspect Accelerate of hiding regulatory setbacks which consequently led to their losses.
On October 21, 2022, after the market closed, Accelerate (AXDX) disclosed a request from the U.S. FDA to immediately discontinue the marketing and distribution of its Accelerate Arc system and related BC Kit for a particular diagnostic use.
  • On this news, $AXDX fell 39% and lost over $9 million of its market capitalization, seriously damaging shareholders.
Considering all the information, investors might have grounds to suspect that Accelerate and its executives were involved in unlawful business practices and failed to timely disclose regulatory setbacks which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
22 October 2022
Collecting participants…

Accelerate Diagnostics Inc

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accel...

    Ticker
    AXDX.US
    ISIN
    US00430H1023
    CIK
    727207
    Sector
    Healthcare
    Industry
    Medical Devices
    Country
    USA
    Address
    3950 South Country Club Road, Tucson, AZ, United States, 85714